Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...
The United States, whose deep cuts to foreign aid this year under President Trump have severely impacted Africa’s health ...
Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval ...
Merck said on Wednesday that its experimental oral HIV treatment met the main goal of a late-stage trial. The company said ...
The first gene-editing therapies for HIV/Aids are entering trials but the virus is proving once again that it is a master at ...
News Medical on MSN
Medicaid Expansion Increases Access to HIV Prevention Medication for High-Risk Populations
Medicaid expansion under the Affordable Care Act (ACA) significantly increased the number of people at risk of HIV diagnosis ...
Gilead’s investigational drug combo bic/len could help lower the pill burden in patients with virologically suppressed HIV ...
APPLIN: After nearly 20 years in HIV care, I’ve seen that HIV follows people through every season of life. When life is stable, patients stay in care and maintain suppression, but when challenges ...
News-Medical.Net on MSN
Investigating the impact of starting HIV drugs within days of infection
Despite effective HIV medication, the immune system of people with HIV remains disrupted in the long term. Researchers at ...
ICA to screen Independent documentary amid unprecedented cuts to global HIV/AIDs response - To mark World AIDS Day, the ...
Deniz Gökengin thinks colleagues view her as “a very serious, hardworking, meticulous, control-freak type of person”. But she ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback